The Efficacy of Local Treatment for Recurrent Endometrial Cancer
Journal of Obstetrics and Gynaecology Research · 2026-06 · 52 (6)
DOI: 10.1111/jog.70354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 01.06.2026. Verfasst von Mari Igasaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Aim
This study aimed to evaluate the efficacy of local treatment in patients with sporadic recurrent endometrial cancer.
Methods
We retrospectively reviewed patients who received treatment for first recurrence of endometrial cancer at our institution between 2012 and 2024. Sporadic recurrence was defined as the presence of up to three metastatic lesions within any single organ, with no more than five total lesions, excluding vaginal cuff recurrence. Patient characteristics, recurrence patterns, and clinical outcomes, including progression‐free survival (PFS) and overall survival (OS), were compared between patients receiving local and systemic treatment.
Results
A total of 67 patients met the eligibility criteria, of whom 37 received local treatment and 30 received systemic treatment. The baseline characteristics did not differ significantly between the two groups. All 11 patients with recurrent lesions involving the two anatomical regions were treated systemically. In the analysis restricted to single‐region recurrences, 37 and 19 patients were included in the local and systemic treatment groups, respectively. In the single‐region cohort, local treatment was associated with significantly improved progression‐free survival (PFS) in Kaplan–Meier analysis (3‐year PFS: 53.7% vs. 15.8%, p = 0.007) and univariate analysis (HR 0.40, p = 0.011), although this was not significant in multivariable analysis (HR 0.50, p = 0.063). No significant difference in overall survival was observed. Patients with shorter treatment‐free intervals trended to have poorer outcomes.
Conclusions
Local treatment may provide a clinical benefit in selected patients with sporadic recurrent endometrial cancer confined to a single region, excluding those with vaginal cuff recurrence. However, this benefit may be influenced by patient selection. Further prospective studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
ORCID-Profile: Mari Igasaki, Akiko Furusawa
Zitieren
APA
Igasaki, M., Furusawa, A., Kunishi, M., Misaka, S., Kamiya, N., Kawamura, A., Kado, N., Mochizuki, A., Takahashi, N., & Takekuma, M. (2026). The Efficacy of Local Treatment for Recurrent Endometrial Cancer. Journal of Obstetrics and Gynaecology Research, 52(6). https://doi.org/10.1111/jog.70354
Vancouver
Igasaki M, Furusawa A, Kunishi M, Misaka S, Kamiya N, Kawamura A, et al. The Efficacy of Local Treatment for Recurrent Endometrial Cancer. Journal of Obstetrics and Gynaecology Research. 2026;52(6). doi:10.1111/jog.70354
BibTeX
@article{Igasaki2026,
author = {Igasaki, Mari and Furusawa, Akiko and Kunishi, Mao and Misaka, Satoki and Kamiya, Natsuko and Kawamura, Atsuko and Kado, Nobuhiro and Mochizuki, Ayako and Takahashi, Nobutaka and Takekuma, Munetaka},
title = {The Efficacy of Local Treatment for Recurrent Endometrial Cancer},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2026},
volume = {52},
number = {6},
doi = {10.1111/jog.70354}
}
EUVIMED